@article{51d99988991e47c88f6917c08754f5c6,
title = "Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease",
abstract = "Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders.Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls. All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease.Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD. We found significant associations between macular thickness and global cortical atrophy [β -0.358; P = .01] and parietal cortical atrophy on magnetic resonance imaging [β -0.371; P < .01] in AD cases.Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.",
keywords = "Retinal thickness, Cortical atrophy, Alzheimer's disease, Neurodegeneration, Biomarker",
author = "Haan, {Jurre den} and {van de Kreeke}, {Jacoba A} and Elles Konijnenberg and Kate, {Mara Ten} and Braber, {Anouk den} and Frederik Barkhof and {van Berckel}, {Bart N} and Teunissen, {Charlotte E} and Philip Scheltens and Visser, {Pieter Jelle} and Verbraak, {Frank D} and Bouwman, {Femke H}",
note = "Funding Information: This study was designed and conducted according to the Declaration of Helsinki, and the study protocol was approved by the Ethical Committee of the Amsterdam Medical Center, location VUmc. All participants gave their written informed consent for participation in this study in the presence of their caregiver. The authors thank all patients, controls, and their families for their participation in our study and Heidelberg for providing the SD OCT for the eye imaging. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. The EMIF-AD study received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant number 115372) and in kind from GE Healthcare (PET tracer). F.B. is supported by the NIHR biomedical research center at UCLH. Funding Information: This study was designed and conducted according to the Declaration of Helsinki, and the study protocol was approved by the Ethical Committee of the Amsterdam Medical Center, location VUmc. All participants gave their written informed consent for participation in this study in the presence of their caregiver. The authors thank all patients, controls, and their families for their participation in our study and Heidelberg for providing the SD OCT for the eye imaging. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds . The clinical database structure was developed with funding from Stichting Dioraphte . The EMIF-AD study received support from the EU/ EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant number 115372 ) and in kind from GE Healthcare (PET tracer). F.B. is supported by the NIHR biomedical research center at UCLH . Publisher Copyright: {\textcopyright} 2019 The Authors",
year = "2019",
month = dec,
doi = "10.1016/j.dadm.2019.05.002",
language = "English",
volume = "11",
pages = "463--471",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "1",
}